XML 49 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaboration and Licensing Agreements (Tables)
 12 Months Ended
Dec. 31, 2024
Collaboration and Licensing Agreements [Abstract]  
Schedule of Revenue
Disaggregation of total revenues by nature is as follows:
Year Ended December 31,
(in thousands)202420232022
Product sales, net
$319,196 $82,526 $15,600 
Product supply revenue11,649 6,121 1,527 
Licensing revenue78 35,809 35,031 
Non-cash royalty revenue related to the sale of future royalties2,692 — — 
Total revenues$333,615 $124,456 $52,158 
Total product sales, net was as follows:
Year Ended December 31,
(in thousands)202420232022
Product sales, net
IBSRELA$158,286 $80,062 $15,600 
XPHOZAH160,910 2,464 — 
Total product sales, net$319,196 $82,526 $15,600 
The following table summarizes total revenue by collaboration partner:
Year Ended December 31,
(in thousands)202420232022
Licensing revenue
Kyowa Kirin
$— $30,000 $35,000 
Fosun Pharma
— 5,000 — 
METiS
— 750 — 
Knight
78 59 31 
Total licensing revenue
$78 $35,809 $35,031 
Product supply revenue   
Kyowa Kirin
11,649 6,092 1,518 
Fosun Pharma
— 29 9 
Total supply revenue
$11,649 $6,121 $1,527 
Non-cash royalty revenue related to the sale of future royalties   
Kyowa Kirin
$2,692 $— $— 
Schedule of Deferred Revenue Balances
The following table presents changes in our current and non-current deferred revenue balances, which are all attributable to Kyowa Kirin:
20242023
(in thousands)CurrentNon-CurrentCurrentNon-Current
Balance at January 1,
$7,182$8,644$4,211$9,025
Prepaid product supply3,7168,2121,5475,629
Product supply delivered(9,836)—(4,586)—
Reclassify amounts to be recognized in the next twelve months9,624(9,624)6,010(6,010)
Balance at December 31,$10,686$7,232$7,182$8,644